References
- Hogan M. AHRQ finds breast cancer tops list of new genetic oncology tests. The Pink Sheet Daily (3 January 2011).
- Hamburg MA, Collins FS. The path to personalized medicine. N. Engl. J. Med.363, 301–304 (2010).
- Evans JP, Meslin EM, Marteau TM, Caulfield T. Deflating the genomic bubble. Science331, 861–862 (2011).
- McCarthy MI. Genomics, Type 2 diabetes, and obesity. N. Engl. J. Med.363, 2339–2350 (2010).
- Merrill J. Companion diagnostics: a business area fraught with challenges ahead. The Pink Sheet Daily (15 March 2011).
- Opinion, Association for Molecular Pathology et al. v. United States Patent and Trademark Office et al. CA No. 1:09-CV-4515-RWS (southern district of New York filed March 29 2010).
- Hollmer M. Personalized medicine coalition renews pitch for modern coding system. The Gray Sheet (13 December 2010).
- Usdin S. Regulation: new diagnostics pathway. BioCentury (6 December 2010).
- Oversight of laboratory developed tests, FDA Docket No. FDA-2010-N-0274,75 Fed. Reg. 34, 463 (17 June 2010).
- Ardekani AM, Petricoin EF 3rd, Hackett JL. Molecular diagnostics: an FDA perspective. Expert Rev. Mol. Diagn.3(2), 129–140 (2003).
- US FDA: United States Code Title 21 § 321(h)(1).
- US FDA: Code of Federal Regulations Title 21 § 809.3.
- In Vitro Diagnostics: The Complete Regulatory Guide. Danzis SD, Flannery EJ (Eds). Food and Drug Law Institute. Washington, DC, USA, 129–147 (2010).
- US FDA: Code of Federal Regulations Title 21 § 820.30.
- US FDA: Code of Federal Regulations Title 21 § 809.10.
- US FDA: Code of Federal Regulations Title 21 Parts 807 and 814.
- Makower J, Meer A, Denend L. FDA Impact on U.S. Medical Technology Innovation – A Survey of Over 200 Medical Technology Companies. Pricewaterhouse Coopers, New York, NY, USA (November 2010).
- US FDA: Code of Federal Regulations Title 21 § 10.115.
- US FDA: United States Code Title 21 § 360c.
- US FDA: Code of Federal Regulations Title 21 Part 820.
- Letter from the patient, consumer, and Public Health Coalition to the Hon. Joe Barton, Ranking Member, Committee on Energy and Commerce, US House of Representatives (27 October 2010).
- 510(k) cleared medical device: Prodesse ProFlu+ Assay (K081030).
- 510(k) cleared medical device: Quest Diagnostics, Inc., Focus Diagnostics, Simplexa Flu A/B & RSV Assay (K102170).
- US FDA: United States Code Title 21 § 360c(a)(1)(B).
- US FDA: United States Code Title 21 § 360c(a)(1)(C).
- FDA, Permarket Approval Application. Virapap Human Papillomavirus DNA Detection Kit, Digene Diagnostics, Inc. (P880009).
- FDA, Permarket Approval Application. DakoCytomation Her2 FISH pharmDx™ Kit (P040005).
- US FDA: Code of Federal Regulations Title 21 § 807.20.
- US FDA: Code of Federal Regulations Title 21 Part 803.
- US FDA: Code of Federal Regulations Title 21 Part 806.
- US FDA: United States Code Title 21 § 352(a) and (f)(1).
- Mansfield EA, Director, Personalized Medicine, Office of In vitro Diagnostic Device Evaluation and Safety, Center for Devices and Radiological Health, FDA, FDA’s (emerging) oversight of laboratory-developed tests webinar, The Food and Drug Law Institute webinar (4 August 2010).
- US FDA: Code of Federal Regulations Title 21 § 866.3510.
- Riegel v. Medtronic, Inc. 552 U.S. 312 (2008).
- US FDA: United States Code Title 21 § 360c(i).
- US FDA: Code of Federal Regulations Title 21 § 807.
- Hines JZ, Lurie P, Yu E, Wolfe S. Left to their own devices: breakdowns in United States medical device premarket review. PloS Med.7(7), e1000280 (2010).
- The Coalition for 21st Century Medicine comments to FDA Docket No. FDA2010-N-0274, oversight of laboratory developed tests (15 September 2010).
- US FDA: United States Code Title 21 § 360c(a)(1)(B), (e)(2).
- US FDA: United States Code Title 21 § 360e(d)(2).
- US FDA: United States Code Title 21 § 360c(a)(3)(B), (a)(3)(D).
- US FDA: United States Code Title 21 § 360e(c).
- US FDA: Code of Federal Regulations Title 21 Part 814.
- US FDA: Code of Federal Regulations Title 21 § 807.81(a)(3).
- US FDA: Code of Federal Regulations Title 21 § 814.39.
- Gottlieb S. Will regulation thwart the personalization of medicine? Molecular diagnostics and the expanding role of the FDA, health policy outlook. American Enterprise Institute for Public Policy Research, Washington, DC, USA (2010).
- Medtronic, Inc. v. Lohr, 518 U.S. 470 (1996); Riegel v. Medtronic, Inc. 552 U.S. 312 (2008).
- US FDA: Federal Food, Drug, and Cosmetic Act. Section § 520(g)(7).
- Douglas JA, Gruber SB, Meister KA et al. History and molecular genetics of Lynch syndrome in family G: a century later. JAMA294, 2195–2202 (2005).
- US FDA: Code of Federal Regulations Title 21 §§ 868.5450 (Respiratory Gas Humidifier) and 868.5895 (Continuous Ventilator).
- Hamburg MA. Letter to the Editor, FDA Commissioner: agency is world-class regulator. Wall St. J. (29 December 2010).
- Jabobelli v. Ohio, 378 U.S. 184, 197 (1964) (Stewart J., Concurring).
- Genentech, Inc. Citizen Petition to the FDA requesting all in vitro diagnostic tests intended for use in drug or biologic therapeutic decision making be held to the same scientific and regulatory standards, regardless of whether the tests are developed and sold by device manufacturers as diagnostic test ‘kits’ or are developed by clinical laboratory companies for in-house testing (‘laboratory-developed tests’ or ‘LDTs’) FDA-2008-P0638 (5 December 2008).
- McDermott U, Downing JR, Stratton MR. Genomics and the continuum of cancer care. N. Engl. J. Med.364, 340–350 (2011).
- US FDA: United States Code Title 21 § 360e(c)(3).
- Scherf U. The FDA and molecular testing: regulatory challenges, 2008. Presented at: Molecular Virology Workshop. Daytona Beach, FL, USA, 25 April 2008.
- Sotiriou C, Pusztai L. Gene-expression signatures in breast cancer. N. Engl. J. Med.360, 790–800 (2009).
- Washington Legal Foundation v. Friedman, 13 F. Supp. 2d 51 (D.D.C. 1998).
- Zivinia T, Kondratovich MV, Mansfield E. US FDA and personalized medicine: in vitro diagnostic regulatory perspective. Personalized Medicine7(5), 517–530 (2010).
- Hamburg MA. Innovation, regulation, and the FDA. N. Engl. J. Med.363, 2228–2232 (2010).
Websites
- Schwartz J, Pollack A. Judge invalidates human gene patent. New York Times (29 March 2010) www.nytimes.com/2010/03/30/business/30gene.html (Accessed 20 December 2010)
- Centers for Medicare and Medicaid Services, proposed decision memorandum for pharmacogenomic testing for warfarin response (CAG-00400N) (4 May 2009) www.cms.gov/mcd/viewdraftdecisionmemo.asp?from2=viewdraftdecisionmemo.asp&id=224& (Accessed 20 December 2010)
- Press Release, AdvaMed proposes modernizing regulation of diagnostic tests (13 February 2008) www.advamed.org/MemberPortal/About/NewsRoom/NewsReleases/2008/pr-02-13–08-least_burdensome_reg_dx_tests.htm (Accessed 20 December 2010)
- European Commission Directive 98/79/EC. In vitro diagnostic medical devices (1998) http://ec.europa.eu/enterprise/policies/european-standards/documents/harmonisedstandards-legislation/list-references/iv-diagnostic-medical-devices/index_en.htm (Accessed 20 December 2010)
- Draft guidance for industry and FDA staff, establishing performance characteristics of in vitro diagnostic devices for detection or detection and differentiation of influenza viruses (2008) www.fda.gov/downloads/MedicalDevices/DeviceRegulationandGuidance/GuidanceDocuments/ucm071458.pdf (Accessed 20 December 2010)
- News Release. FDA clears breast cancer specific molecular prognostic test (6 February 2007) www.fda.gov/NewsEvents/Newsroom/PressAnnouncements/2007/ucm108836.htm (Accessed 20 December 2010)
- News Release. FDA clears genetic lab test for warfarin sensitivity (17 September 2007) www.fda.gov/NewsEvents/Newsroom/PressAnnouncements/2007/ucm108984.htm (Accessed 20 December 2010)
- FDA General and Plastic Surgery Devices Panel of the Medical Devices Advisory Committee Meeting related to the premarket approval application for MelaFind, sponsored by MELA Sciences (18 November 2010) www.fda.gov/AdvisoryCommittees/Calendar/ucm223189.htm (Accessed 20 December 2010)
- Guidance for Industry and FDA Staff – Class II Special Controls Guidance Document: instrumentation for clinical multiplex test systems www.fda.gov/MedicalDevices/DeviceRegulationandGuidance/GuidanceDocuments/ucm077819.htm (Accessed 20 December 2010)
- CDRH Preliminary Internal Evaluations – Volume I: 510(k) Working Group Preliminary Report and Recommendations (August 2010) www.fda.gov/downloads/AboutFDA/CentersOffices/CDRH/CDRHReports/UCM220784.pdf (Accessed 20 December 2010)
- Preliminary report, review of the ReGen Menaflex®: departures from processes, procedures, and practices leave the basis for a review decision in question (September 2009) www.fda.gov/downloads/NewsEvents/PublicHealthFocus/UCM183642.pdf (Accessed 20 December 2010)
- FDA clears test that helps identify type of cancer in tumor sample (31 July 2008) www.fda.gov/NewsEvents/Newsroom/PressAnnouncements/2008/ucm116931.htm (Accessed 20 December 2010)
- Guidance for industry and CDRH staff – New Section 513(f)(2) – evaluation of automatic class III designation (19 February 1998) www.fda.gov/downloads/MedicalDevices/DeviceRegulationandGuidance/GuidanceDocuments/ucm080197.pdf (Accessed 20 December 2010)
- Ladin Z, Imhoff M. FDA review patterns of ‘de novo’ submissions. Boston Medtech Advisors (June 2010) www.bmtadvisors.com/docs/2010_06_10_FDA%20Review%20Patterns%20of%20De%20Novo%20Submissions_Final.pdf (Accessed 30 December 2010)
- FDA permits marketing of first test for most common cause of gastroenteritis outbreaks. FDA News Release www.fda.gov/NewsEvents/Newsroom/PressAnnouncements/ucm244331.htm. (Accessed 20 December 2010)
- OVA1™ Test (K081754) www.accessdata.fda.gov/scripts/cdrh/cfdocs/cfpmn/pmn.cfm?ID=28199 (Accessed 20 December 2010)
- FDA warning letter issued to Beckman Coulter, Inc. (21 June 2010) www.fda.gov/ICECI/EnforcementActions/WarningLetters/ucm217576.htm (Accessed 29 December 2010)
- Deciding When to Submit a 510(k) for a Change to an Existing Device (K97–1) (10 January 1997) www.fda.gov/downloads/MedicalDevices/DeviceRegulationandGuidance/GuidanceDocuments/ucm080243.pdf (Accessed 29 December 2010)
- PMA Supplements and Amendments Link (Accessed 30 December 2010)
- FDA Transparency Initiative www.fda.gov/AboutFDA/Transparency/default.htm (Accessed 29 December 2010)
- Request for designation decision letters, Office of Combination Products www.fda.gov/CombinationProducts/JurisdictionalInformation/RFDJurisdictionalDecisions/RedactedDecisionLetters/default.htm (Accessed 30 December 2010)
- News Release, FDA clears breast cancer specific molecular prognostic test (6 February 2007) www.fda.gov/NewsEvents/Newsroom/PressAnnouncements/2007/ucm108836.htm (Accessed 20 December 2010)
- Guidance for industry and FDA staff, replacement reagent and instrument family policy (December 2003) www.fda.gov/downloads/MedicalDevices/DeviceRegulationandGuidance/GuidanceDocuments/ucm071465.pdf (Accessed 29 December 2010)
- Guidance for industry – good reprint practices for the distribution of medical journal articles and medical or scientific reference publications on unapproved new uses of approved drugs and approved or cleared medical devices (January 2009) www.fda.gov/RegulatoryInformation/Guidances/ucm125126.htm. (Accessed 20 December 2010)